Integra Lifesciences Holdings (IART) Non-Current Deferred Tax Liability (2016 - 2025)
Integra Lifesciences Holdings' Non-Current Deferred Tax Liability history spans 17 years, with the latest figure at $58.3 million for Q3 2025.
- For Q3 2025, Non-Current Deferred Tax Liability fell 15.46% year-over-year to $58.3 million; the TTM value through Sep 2025 reached $58.3 million, down 15.46%, while the annual FY2024 figure was $263.4 million, 21.72% up from the prior year.
- Non-Current Deferred Tax Liability for Q3 2025 was $58.3 million at Integra Lifesciences Holdings, down from $60.1 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $263.4 million in Q4 2024 and bottomed at $31.4 million in Q1 2024.
- The 5-year median for Non-Current Deferred Tax Liability is $65.3 million (2021), against an average of $89.5 million.
- The largest annual shift saw Non-Current Deferred Tax Liability soared 376.76% in 2022 before it tumbled 49.05% in 2024.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $45.8 million in 2021, then skyrocketed by 376.76% to $218.3 million in 2022, then fell by 0.87% to $216.4 million in 2023, then rose by 21.72% to $263.4 million in 2024, then crashed by 77.87% to $58.3 million in 2025.
- Per Business Quant, the three most recent readings for IART's Non-Current Deferred Tax Liability are $58.3 million (Q3 2025), $60.1 million (Q2 2025), and $57.6 million (Q1 2025).